Training cohort (n = 233) | Validation cohort 1 (n = 16) | Validation cohort 2 (n = 20) | ||||
---|---|---|---|---|---|---|
No. of patients | % | No. of patients | % | No. of patients | % | |
Sex | ||||||
Male | 208 | 89.3 | 15 | 93.75 | 17 | 85.0 |
Female | 25 | 10.7 | 1 | 6.25 | 3 | 15.0 |
Age, years | ||||||
Median | 53.0 | 53.0 | 53.5 | |||
IQR | 48.0–60.0 | 47.3–61.8 | 47.8–62.0 | |||
LT criteria | ||||||
Milan | 95 | 40.8 | 14 | 87.5 | 14 | 70.0 |
Hangzhou | 42 | 18.0 | 2 | 12.5 | 4 | 20.0 |
Over Hangzhou | 96 | 41.2 | 0 | 0 | 2 | 10.0 |
Smoke | ||||||
Yes | 128 | 54.9 | 13 | 81.2 | 12 | 60.0 |
No | 105 | 45.1 | 3 | 18.8 | 8 | 40.0 |
Alcohol | ||||||
Yes | 77 | 33.0 | 10 | 62.5 | 8 | 40.0 |
No | 156 | 67.0 | 6 | 37.5 | 12 | 60.0 |
BMI | ||||||
Median | 22.8 | 23.9 | 21.5 | |||
IQR | 21.1–25.1 | 21.2–25.6 | 19–22.9 | |||
AFP, ng/mL | ||||||
Median | 13.9 | 31.1 | 174.6 | |||
IQR | 3.4–256.8 | 6.2–426.1 | 6.9–2915.2 | |||
CEA, ng/ml | ||||||
Median | 2.6 | 1.3 | 2.8 | |||
IQR | 1.8–4.1 | 1.0–1.9 | 1.8–3.8 | |||
TB, μmol/mL | ||||||
Median | 26.0 | 25.1 | 26.1 | |||
IQR | 15–55.5 | 10.4–120.8 | 15.7–76.6 | |||
Albumin, g/L | ||||||
Median | 34.0 | 37.9 | 35.8 | |||
IQR | 30.4–38.3 | 34.5–40.7 | 18.3–44.1 | |||
ALT, U/L | ||||||
Median | 34.0 | 33.5 | 35.8 | |||
IQR | 20.5–60.5 | 21.5–62.8 | 18.3–44.1 | |||
AST, U/L | ||||||
Median | 45.0 | 32.0 | 47.6 | |||
IQR | 31–80 | 24.3–110.3 | 26.2–74.1 | |||
Hypertension | ||||||
Yes | 40 | 17.2 | 2 | 12.5 | 5 | 25.0 |
No | 193 | 82.8 | 14 | 87.5 | 15 | 75.0 |
Diabetes | ||||||
Yes | 26 | 11.2 | 2 | 12.5 | 4 | 20.0 |
NO | 207 | 88.8 | 14 | 87.5 | 16 | 80.0 |
Ascites | ||||||
No | 142 | 60.9 | 9 | 56.3 | 13 | 65.0 |
Mild | 70 | 30.0 | 6 | 37.5 | 1 | 5.0 |
Severe | 21 | 9.1 | 1 | 6.3 | 6 | 30.0 |
HBeAg | ||||||
Positive | 56 | 24.0 | 15 | 93.8 | 17 | 85.0 |
Negative | 177 | 76.0 | 1 | 6.2 | 3 | 15.0 |
Blood type | ||||||
Matched | 189 | 81.1 | 15 | 93.8 | 19 | 95.0 |
Unmatched | 44 | 18.9 | 1 | 6.2 | 1 | 5.0 |